monday et judg balkman releas opinion state oklahoma vs
johnson johnson subsidiari relat opioid judg balkman rule
engag fals mislead market caus public nuisanc moreov judg
balkman rule public harm could abat equit abat
order pay million thought
million million want pay view
compani plan appeal rule far less state oklahoma
ask billion less believ market brace
thu view million favor believ could ultim lower
way comparison purdu privat settl million teva cover
 prasad settl million even unsuccess appeal
effort billion cash/secur gener billion free cash
litig like remain overhang stock state
caus opioid crisi neither fact law support outcom
confid strong ground appeal appeal process like take two
year besid oklahoma on-going feder multi-district litig case
current schedul octob besid opioid involv
legal matter signific talc litig
rate share equal weight believ share like continu trade
discount sum-of-the-part valuat due litig overhang
updat ep forecast post review ep forecast
reduc maintain price target roll forward methodolog
incorpor versu pt use sum-of-the-part assess
appli blend target pe ep sinc
trade market multipl current trade ep
believ litig overhang share could trade closer market pe
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight continu like jnj
continu innov bode well
longer term howev believ litig concern
like remain overhang stock along
concern regard near-term biosimilar
gener pressur also believ street
ep estim may high rate share equal
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
legal liabil unfortun overhang share
legal liabil includ product liabil normal cours busi
healthcar industri johnson johnson product liabil becom signific
overhang stock creat headlin creat signific volatil well
signific product liabil incur recent year depuy asr hip system
 initi world-wide voluntari recal august sinc compani record
total million pre-tax million post-tax charg relat depuy
asr system signific product liabil accru includ pinnacl
composit mesh sinc accru nearli billion legal expens
 note accrual product liabil claim record undiscount
basi probabl liabil incur amount liabil
reason estim base exist inform actuari determin
estim applic also note accru estim legal defens
cost need defend matter cost probabl reason
estim moreov note extent advers verdict render
 record accrual loss determin probabl
reason estim
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
